Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression.

OBJECTIVE: Current pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in...

詳細記述

書誌詳細
主要な著者: Miskowiak, K, Vinberg, M, Harmer, C, Ehrenreich, H, Kessing, L
フォーマット: Journal article
言語:English
出版事項: 2012

類似資料